Anebulo Pharmaceuticals 8-K Filing Report: Key Insights & Stock Information

Here’s the extracted key information and insights from the provided financial report section:

Company Information

• Company Name: Anebulo Pharmaceuticals, Inc.
• CIK: 0001815974
• SEC File Number: 001-40388
• EIN: 85-1170950
• Address: 1017 Ranch Road 620 South Suite 107, Lakeway, TX 78734
• Contact Number: (512) 598-0931

Filing Details

• Filing Type: Form 8-K
• Filing Date: February 14, 2025

Stock Information

• Common Stock Par Value: $0.001 per share
• Ticker Symbol: ANEB
• Exchange: NASDAQ

Financial Metrics

• Reporting Date: February 14, 2025
• Currency Unit: USD
• Shares: The report contains specific measures related to shares, although the exact number of shares is not specified in the provided excerpt.

Contextual Notes

• The report follows the XBRL format, which is used for the electronic filing of financial data with the SEC.
• The reporting period indicates that the information is as of a single day (February 14, 2025).

Insights

1. Recent Filing: The 8-K filing suggests that Anebulo Pharmaceuticals has made a significant announcement or event that is material to investors and required immediate disclosure.
2. Stock Listing: The company is listed on NASDAQ, indicating it is publicly traded and likely subject to rigorous regulatory scrutiny.
3. Minimal Par Value: The low par value of common stock suggests a typical structure for a biotech firm, which may be relevant for investors assessing the capital structure and potential dilution risks.

This summary provides a concise overview of the critical aspects of Anebulo Pharmaceuticals' financial report section.